<DOC>
	<DOCNO>NCT01714713</DOCNO>
	<brief_summary>This study conduct investigate safety prolong exposure EVP-6124 subject Schizophrenia receive stable dose atypical antipsychotic complete double-blind treatment study EVP-6124-015 EVP-6124-016 .</brief_summary>
	<brief_title>A 26-Week Extension Study EVP-6124 ( Alpha-7 nAChR ) Adjunctive Pro-Cognitive Treatment Schizophrenia Subjects Chronic Stable Atypical Antipsychotic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Nicotinic Agonists</mesh_term>
	<criteria>Completion Day 182 visit previous 26week doubleblind study ( EVP6124015 EVP6124016 ) . Subject sign informed consent extension study , indicate subject understands purpose procedure require study , initiation extension study specific procedure . Subjects unable provide inform consent include study No clinically significant change subject 's medical status participation EVP6124015 EVP6124016 . Any significant change health care status impact subject eligibility review investigator sponsor casebycase basis . In opinion investigator , extension treatment best interest subject . Fertile , sexually active subject ( men woman ) must use effective method contraception study . Females female partner male must surgically sterile ( hysterectomy bilateral tubal ligation ) , postmenopausal least 1 year , willing practice adequate method contraception childbearing potential ( defined consistent use combine effective method contraception [ include least one barrier method ] ) . Female subject must negative urine pregnancy test predose Day 1 . Significant risk suicidal violent behavior , determine investigator . Significant risk suicidal behavior define 1 ) suicidal ideation endorse item 4 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) ; 2 ) suicidal behavior detect CSSRS ; 3 ) psychiatric interview examination . Adverse event previous study ( EVP6124015 EVP6124016 ) resolve , moderate great severity judge possibly relate related study drug think investigator contraindication study participation . Any condition would make subject , opinion investigator , unsuitable study . Female subject pregnant . Subjects receive investigational treatment participation either EVP6124015 EVP6124016 assign study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Cognition</keyword>
	<keyword>Cognition Impairment</keyword>
	<keyword>Alpha-7 nAChR</keyword>
</DOC>